Andere talen Novo Nordisk A/S

Aandelen

NOVO B

DK0062498333

Farmaceutische producten

Beurs gesloten - Nasdaq Copenhagen Andere beurzen 17:20:00 20-07-2026			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
328,00 ^DKK	-0,58%		+1,11%	+0,85%

17:41	Aspen Pharmacare krijgt Canadese goedkeuring voor generieke Ozempic na verloop patent Novo	RE
16:41	Aspen Pharmacare krijgt Canadese goedkeuring voor generieke versie van Ozempic	RE

Andere talen

17:41	Aspen Pharmacare wins Canada approval for generic Ozempic after Novo patent expiry
16:41	Aspen Pharmacare wins Canada approval for generic Ozempic injection
15:22	Novo Nordisk's Wegovy Approved in India for Fatty Liver Disease Treatment
14:32	Novo Nordisk A/S - share repurchase programme
07:03	Could AI chip boom make ASML Europe's first trillion-dollar firm?
18/07	Abbott investigates two separate cyber incidents, says no operations affected
17/07	Novo Nordisk to launch lower-cost Ozempic copy in South Africa
17/07	European Equities Mixed in Friday Trading; ASML to Give Staff One-Time Bonus
17/07	Novo Nordisk's Wegovy Gets Indian Regulator Nod to Treat Aggressive Fatty Liver Disease
17/07	Novo Nordisk's Wegovy Approved for Fatty Liver Disease Treatment by India's Drug Regulator
17/07	US companies face rise in cyber attacks
17/07	US companies face rise in cyber attacks
17/07	India approves Novo Nordisk's obesity drug Wegovy for fatty liver disease
17/07	MORNING BRIEFING - Deutschland/Europa
16/07	Uneinheitlich - Novo Nordisk erhält EU-Zulassung für Wegovy in Pillenform
16/07	European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday
16/07	Börsen bauen Verluste aus - Telenor-Zahlen enttäuschen
16/07	Etwas leichter - Technologie-Werte rutschen weiter ab
16/07	Avis d'analystes du jour : ASML et Richemont font le plein, Evotec encore sanctionnée
16/07	Salve de résultats et puces schizophrènes
16/07	MORNING BRIEFING - Deutschland/Europa
16/07	United Laboratories Unit Receives $13.5 Million Milestone Payment From Novo Nordisk
16/07	Les valeurs à suivre à Paris et en Europe (actualisé)
16/07	Novo Nordisk Gets Regulatory Nod to Market Weight Loss Pill in EU
15/07	Novo Nordisk Receives European Commission Approval of Wegovy® Pill as First Oral Glp-1 for Weight Management in the Eu; Single, Ready-To-Use Pen for Higher Dose 7.2 Mg Also Approved